Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. KTOS
6. AON
7. TMUS
8. LBRX
9. BMY
10. MRK

Go back to Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance

Ionis reports third quarter 2025 financial results and highlights progress on key programs

October 29, 2025 7:00 AM EDT

- TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 -

- DAWNZERA (donidalorsen) launch off to encouraging start -

- Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end

- Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology launch in 2026 -

- Increasing 2025 financial guidance driven by continued strength across the business

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis... More